32 results
6-K
EX-99.1
ARGX
Argen X SE
21 Mar 24
Current report (foreign)
6:07am
and heart. Myositis can be very severe and disabling and have a material impact on quality of life. Initially these Myositis were classified as either DM … catalogues for the national medical insurance program regularly, and the tier under which a drug or device will be classified, both of which affect
6-K
EX-99.1
ARGX
Argen X SE
28 Nov 23
Current report (foreign)
6:01am
with sustained platelet count response, an extended primary endpoint analysis between weeks 17 and 24, and the incidence and severity of WHO-classified bleeding
6-K
EX-99.2
ARGX
Argen X SE
27 Jul 23
Current report (foreign)
6:02am
to the closing price of such securities at each reporting date (classified as level 1 in the fair value hierarchy), resulting in a change in fair value
424B5
rj7wg
20 Jul 23
Prospectus supplement for primary offering
4:51pm
424B5
rs52olk6
17 Jul 23
Prospectus supplement for primary offering
4:42pm
6-K
EX-99.1
bdjesc8lb7x 61
12 Dec 22
Current report (foreign)
4:01pm
6-K
EX-99.2
czr9znt8f ox
28 Jul 22
Current report (foreign)
8:29am
6-K
EX-99.2
dmsa065cxy718ox6p
5 May 22
Current report (foreign)
7:53am
424B5
coo9a3horza7ms bt
25 Mar 22
Prospectus supplement for primary offering
4:21pm
424B5
ujwmi6eys4e
22 Mar 22
Prospectus supplement for primary offering
4:33pm
F-3ASR
3bqi27v
29 Jul 21
Automatic shelf registration (foreign)
8:22am
6-K
EX-99.2
ohrphf9m0hrpa4kdrn9
29 Jul 21
Current report (foreign)
6:10am
424B5
fua1za
4 Feb 21
Prospectus supplement for primary offering
4:43pm
424B5
ei4ilgdlw
1 Feb 21
Prospectus supplement for primary offering
4:44pm
424B5
bh1ex3rac2 3nuj
29 May 20
Prospectus supplement for primary offering
4:11pm